Apimeds Pharmaceuticals US, Inc. 8-K

What Happened
Apimeds Pharmaceuticals US, Inc. announced by 8-K (Item 8.01) that its stockholders approved a 1-for-10 reverse stock split by written consent on December 1, 2025. The company mailed a definitive Information Statement under Rule 14c-2 and expects to file a Charter Amendment with the Delaware Secretary of State on or about March 25, 2026. The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on March 26, 2026, and the company expects its common stock to begin trading on a split-adjusted basis on the NYSE American (symbol: APUS) at the open of trading on March 26, 2026.

Key Details

• Stockholder approval by written consent: December 1, 2025.
• Waiting Period: Reverse split will not be effective until at least 20 calendar days after mailing the definitive Information Statement.
• Expected filings/dates: Charter Amendment filing on or about March 25, 2026; effective date 12:01 a.m. ET March 26, 2026.
• Conversion ratio and trading: Every 10 issued and outstanding shares will be combined into 1 share; trading on NYSE American expected to reflect the split on March 26, 2026.
• New CUSIP after the split: 03771D201.

Why It Matters
A reverse stock split reduces the number of outstanding shares and proportionally increases the per-share price. For investors, this means brokerage account holdings and share counts will be adjusted (10 old shares → 1 new share) and the stock will trade under a new CUSIP. Investors should check broker statements after the effective date for updated share counts and confirm how fractional shares (if any) will be treated, and be aware trading may be affected when the market opens on the effective date.